Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2021-08-03

Clinical Trial Update: Adjuvant Melatonin for Prevention of Lung Cancer Recurrence and Mortality [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating adjuvant melatonin for prevention of lung cancer recurrence and mortality has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Melatonin (melatonin)

Snippet

Sponsor: The Canadian College of Naturopathic Medicine | Conditions: Non Small Cell Lung Cancer | Phase 3 | Status: COMPLETED | Results posted: 2021-08-03